Utility of Lp-PLA2 in lipid-lowering therapy

American Journal of Therapeutics
Sreekanth Racherla, Rohit Arora

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker. It is so named because of its association with low-density lipoprotein in plasma. Atherosclerosis is an inflammatory disease. Lp-PLA2 is recognized as a risk marker in primary or secondary prevention of atherosclerosis. Elevated Lp-PLA2 levels are associated with the increased risk for cardiovascular events, even after multivariable adjustment for traditional risk factors. Patients with dyslipidemia are shown to benefit largely from the modification of Lp-PLA2. The degree of coronary artery disease (0-, 1-, 2-, or 3-vessel disease) and plasma low-density lipoprotein cholesterol significantly correlated to Lp-PLA2 levels. The low biologic fluctuation and high vascular specificity of Lp-PLA2 make it possible to use a single measurement in clinical decision making, and it also permits clinicians to follow the Lp-PLA2 marker serially. Simvastatin significantly reduces macrophage content, lipid retention, and the intima to media ratio but increased the content of smooth muscle cells in atherosclerotic lesions. Statin treatment markedly reduced Lp-PLA2 in both plasma and atherosclerotic plaques with attenuation of the local inflammatory resp...Continue Reading

References

Jun 21, 2002·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·Noriaki Kume
Sep 12, 2002·Expert Opinion on Therapeutic Targets·Keith E Suckling, Colin H Macphee
Jul 2, 2005·Current Opinion in Lipidology·Colin H MacpheeAndrew Zalewski
Aug 30, 2006·Clinics in Laboratory Medicine·Joseph P McConnell, Daniel M Hoefner
Oct 20, 2006·Biochimica Et Biophysica Acta·Ken Karasawa
Jul 28, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Vasilios G SaougosAlexandros D Tselepis
Jan 29, 2008·Current Medicinal Chemistry·Takayuki MatsumotoKatsuo Kamata
Jul 25, 2008·The American Journal of Cardiology·Marshall A CorsonMichael H Davidson
Sep 4, 2008·Circulation·Patrick W SerruysUNKNOWN Integrated Biomarker and Imaging Study-2 Investigators
Oct 25, 2008·Cardiovascular Drugs and Therapy·Wolfgang Koenig, Natalie Khuseyinova
Nov 26, 2008·European Journal of Nutrition·Maria Weinkouff PedersenErik Berg Schmidt
Dec 4, 2008·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Emile R MohlerRobert L Wilensky
Jun 12, 2009·Medicinski pregled·Vera Jerant-PatićGordana Kozarev
Jun 25, 2009·Current Opinion in Lipidology·Hector M Garcia-Garcia, Patrick W Serruys
Aug 12, 2009·Current Opinion in Lipidology·Robert L Wilensky, Colin H Macphee
Sep 18, 2009·Annals of the New York Academy of Sciences·Joana R BatucaJ Delgado Alves
Oct 3, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Dieuwke De KeyzerEwa Ninio
Dec 5, 2009·Nature Reviews. Immunology·Ira Tabas
Jan 7, 2010·Journal of Cardiovascular Pharmacology·Valerie CroonsGuido R Y De Meyer

❮ Previous
Next ❯

Citations

Feb 11, 2016·Nutrients·Christopher R D'AdamoPatrick F McArdle
Jan 4, 2018·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Michael John PeckRolf Weitkunat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.